Iradimed Net Worth

Iradimed Net Worth Analysis

Iradimed Target Price Consensus

Iradimed Target Price Projection

Iradimed's current and average target prices are 52.10 and 65.00, respectively. The current price of Iradimed is the price at which Iradimed Co is currently trading. On the other hand, Iradimed's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Iradimed Co and the information provided on this page.

Know Iradimed's Top Institutional Investors

Note, although Iradimed's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Iradimed's market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 666.91 M.

Project Iradimed's profitablity

The company has Profit Margin (PM) of 0.26 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.3 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.3.

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Evaluate Iradimed's management efficiency

Iradimed has return on total asset (ROA) of 0.1441 % which means that it generated a profit of $0.1441 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2431 %, meaning that it created $0.2431 on every $100 dollars invested by stockholders. Iradimed's management efficiency ratios could be used to measure how well Iradimed manages its routine affairs as well as how well it operates its assets and liabilities. As of March 18, 2025, Return On Tangible Assets is expected to decline to 0.17. In addition to that, Return On Capital Employed is expected to decline to 0.24. At present, Iradimed's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 3.3 M, whereas Other Assets are forecasted to decline to 1.09.

Iradimed Corporate Filings

Iradimed time-series forecasting models is one of many Iradimed's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Iradimed's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Iradimed Earnings Estimation Breakdown

The calculation of Iradimed's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Iradimed is estimated to be 0.41 with the future projection ranging from a low of 0.39 to a high of 0.43. Please be aware that this consensus of annual earnings estimates for Iradimed Co is based on EPS before non-recurring items and includes expenses related to employee stock options.

Iradimed Earnings Projection Consensus

Iradimed Earnings History

Earnings estimate consensus by Iradimed analysts from Wall Street is used by the market to judge Iradimed's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Iradimed's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods. The current year's Price Earnings To Growth Ratio is expected to grow to 3.23, whereas Retained Earnings are forecasted to decline to about 30.2 M. The current year's Common Stock Shares Outstanding is expected to grow to about 13.1 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 15.5 M.

Hype Prediction Low Estimated High 50.16 52.05 53.94 Details

Intrinsic Valuation Low Real High 46.89 59.76 61.65 Details

Naive Forecast Low Next High 51.49 53.38 55.27 Details

2 Analysts Consensus Low Target High 59.15 65.00 72.15 Details

Note that many institutional investors and large investment bankers can move markets due to the volume of Iradimed assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Iradimed. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Iradimed's stock price in the short term.

Iradimed Earnings per Share Projection vs Actual

Actual Earning per Share of Iradimed refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Iradimed Co predict the company's earnings will be in the future. The higher the earnings per share of Iradimed, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Iradimed Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Iradimed, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Iradimed should always be considered in relation to other companies to make a more educated investment decision.

Iradimed Quarterly Analyst Estimates and Surprise Metrics

Iradimed Corporate Management

When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:

How To Invest In Iradimed Details

Is Iradimed Stock a good investment? Details

What is Iradimed's Net Worth? Details

Largest Health Care Equipment & Supplies Companies View

Largest Health Care Equipment & Services Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details